CanaQuest Medical Corporation is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is also focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder (PTSD), including addiction. It provides a novel master formulation derived from cannabidiol (CBD) + IP formula. The Company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the master formulation, branded as Mentanine, is available for sale via the Companyâs store in the United States. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects. The Companyâs wholly owned subsidiary is ADC BioMedical Corp.
CANAQUEST MEDICAL CORP. 
